secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2021-10-28T23:59:59+00:00
Accession:  0001193125-21-310408
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen Q3 revenue $178.2M (+89% YoY); raises FY 2021 revenue guidance to $655-665M
--------------------------------------------------------------------------------

- Revenue hit a record $178.2M in Q3 2021, up 89% YoY as reported and 77% organically.
- GAAP EPS of $0.58, Adjusted EPS of $0.78; GAAP operating margin rose to 25.4%.
- FY 2021 revenue guidance raised to $655-665M (prior $625-645M); adjusted EPS guidance raised to $2.86-$2.91.
- Completed acquisition of affinity ligands innovator Avitide Inc. during the quarter.
- COVID programs contributed 27% of Q3 revenue; base business grew 49% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312521310408/0001193125-21-310408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312521310408/d83679d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-310408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer